Nakamura S
Second Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1991 Jul;66(4):522-33.
To determine whether or not urinary Alanine aminopeptidase (AAP) could be used as an early marker for diabetic nephropathy, urinary AAP, microalbumin and N-acetyl-beta-D-glucosaminidase (NAG) were measured in 132 diabetic patients and 59 normal subjects. Urinary AAP, microalbumin and NAG in the diabetic patients and the normal subjects were 15.5 +/- 11.7 U/g. Cr and 9.1 +/- 6.9 (P less than 0.01), 27.4 +/- 35.5 mg/g. Cr and 8.4 +/- 4.4 (P = 0.0001), 10. 3 +/- 9.5 U/g. Cr and 3.9 +/- 2.1 (P = 0.0001), respectively. AAP had a moderate correlation with NAG (r = 0.58, P = 0.0001). AAP, microalbumin and NAG showed a slight positive correlation with age (AAP: r = 0.25, P less than 0.01, microalbumin: r = 0.32, P less than 0.01, NAG: r = 0.21, P less than 0.05), although it is significant, and AAP had a positive correlation with urinary protein concentration (r = 0.45, P = 0.0001) in diabetic patients. However, AAP in diabetic patients without proteinuria was higher than that in age-matched normal subjects. Urinary AAP was correlated with the indices of renal tubular damage like NAG, alpha 1-microglobulin and beta 2-microglobulin, so it seemed to be tubular origin but in the patients with clinical proteinuria, it might be partially glomerular origin. Since urine AAP increased in some patients without microalbuminuria and was not influenced by control of blood sugar, AAP could be used as an early marker of diabetic nephropath y in addition to microalbumin and NAG, but the effect of age should be considered in its estimation as in the case of NAG.
为了确定尿丙氨酸氨基肽酶(AAP)是否可作为糖尿病肾病的早期标志物,对132例糖尿病患者和59名正常受试者测定了尿AAP、微量白蛋白和N-乙酰-β-D-氨基葡萄糖苷酶(NAG)。糖尿病患者和正常受试者的尿AAP、微量白蛋白和NAG分别为15.5±11.7 U/g·Cr和9.1±6.9(P<0.01)、27.4±35.5 mg/g·Cr和8.4±4.4(P = 0.0001)、10.3±9.5 U/g·Cr和3.9±2.1(P = 0.0001)。AAP与NAG呈中度相关(r = 0.58,P = 0.0001)。AAP、微量白蛋白和NAG与年龄呈轻度正相关(AAP:r = 0.25,P<0.01;微量白蛋白:r = 0.32,P<0.01;NAG:r = 0.21,P<0.05),虽然具有显著性,且糖尿病患者中AAP与尿蛋白浓度呈正相关(r = 0.45,P = 0.0001)。然而,无蛋白尿的糖尿病患者的AAP高于年龄匹配的正常受试者。尿AAP与肾小管损伤指标如NAG、α1-微球蛋白和β2-微球蛋白相关,因此其似乎起源于肾小管,但在临床蛋白尿患者中,可能部分起源于肾小球。由于一些无微白蛋白尿的患者尿AAP升高且不受血糖控制的影响,除微量白蛋白和NAG外,AAP可作为糖尿病肾病的早期标志物,但在评估时应像评估NAG一样考虑年龄的影响。